文献速递泌尿生殖儿科影像MR

儿童MR尿路造影中呋塞米给药后动态肾脏T2映射用于测量分肾功能

Dynamic Renal T2-mapping After Furosemide Administration for Measurement of Differential Renal Function in Pediatric MR Urography.
PubMed 文献 · Invest Radiol · 2026-07-01

这项前瞻性单中心研究纳入32例临床需要MR尿路造影的儿童,在呋塞米给药期间加做动态T2映射,评估肾T2弛豫时间变化作为分肾功能的替代标志物。结果显示呋塞米后肾实质T2弛豫时间显著升高,基于T2升高速率与T2差值得到的DRF均与Patlak-derived DRF强相关(r=0.81、r=0.80),读者间一致性优秀(ICC=0.94)。

要点

  • 呋塞米后肾实质T2弛豫时间由118.4 ms升至134.8 ms(P<0.001),提示可无对比剂评估肾水含量变化。
  • 基于T2升高速率的SlopeDRF与Patlak-derived DRF强相关(r=0.81)。
  • 基于T2差值的DRF与Patlak-derived DRF强相关(r=0.80),读者间一致性ICC=0.94。

核心结论

  • 呋塞米给药后动态肾脏T2映射与增强MRU的Patlak-derived DRF强相关,可能为儿童提供一种无创、无对比剂且无辐射的量化分肾功能方法。

研究设计与样本

  • 前瞻性单中心研究,2024年6月至2025年3月纳入32例临床需要MR尿路造影的儿童(男16例,中位年龄7岁,IQR 0至11岁),在呋塞米给药期间加做呼吸触发梯度自旋回波(GraSE)序列动态T2映射,以增强MRU的Patlak-derived DRF为参考标准。

关键影像表现/征象

  • 呋塞米给药后肾实质T2弛豫时间较给药前显著升高(给药前118.4 ms,IQR 110.8至124.4;给药后134.8 ms,IQR 126.9至141.3;P<0.001)。
  • 基于T2升高速率计算的分肾功能(SlopeDRF)与Patlak-derived DRF强相关(r=0.81)。
  • 基于给药前至给药后T2差值计算的分肾功能与Patlak-derived DRF强相关(r=0.80)。

诊断标准与关键数值

  • 分肾功能(DRF)通过T2升高速率的斜率(SlopeDRF)以及给药前至给药后T2差值计算,均表达为每侧肾脏对总功能的相对贡献。
  • SlopeDRF与Patlak-derived DRF的Pearson相关系数r=0.81;T2差值DRF与Patlak-derived DRF的r=0.80。
  • 读者间一致性采用组内相关系数(ICC)评估,DRF的ICC=0.94。

临床应用与阅片要点

  • 儿童MR尿路造影中,可在呋塞米给药期间加做呼吸触发GraSE序列动态T2映射,以评估肾实质T2弛豫时间变化。
  • 基于T2升高速率或T2差值可计算分肾功能,与增强MRU的Patlak-derived DRF强相关,可能作为无对比剂、无辐射的替代方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Functional imaging of the kidney in pediatric patients is typically performed using contrast-enhanced MR urography (MRU) or nuclear scintigraphy, both of which require either gadolinium-based contrast agents or ionizing radiation. Furosemide, a loop diuretic routinely used in both modalities to stimulate urinary flow, acutely increases tubular fluid volume. These changes in renal water content can be detected by MRI-based quantitative T2 mapping, which may provide a contrast- and radiation-free alternative for evaluating kidney function.

OBJECTIVE: To assess renal T2 relaxation time changes following intravenous furosemide administration as a surrogate marker for differential renal function (DRF) in pediatric MRU.

MATERIALS AND METHODS: In this prospective single-center study (June 2024 to March 2025), pediatric patients undergoing clinically indicated MRU received additional dynamic T2 mapping during furosemide administration using a respiratory-triggered gradient-and-spin-echo (GraSE) sequence. Two readers independently assessed T2 relaxation time changes. DRF was derived from the slope of the T2 increase (SlopeDRF) as well as from pre-T2 to post-T2 differences, expressed as each kidney's relative contribution to total function. These measures were compared with contrast-enhanced, Patlak-derived DRF (pDRF) using Pearson correlation and Bland-Altman analysis. Interreader agreement was assessed with the intraclass correlation coefficient (ICC).

RESULTS: Thirty-two patients (16 males; median age: 7 y, IQR: 0 to 11) were included. Renal parenchymal T2 relaxation times increased significantly after furosemide administration (pre: 118.4 ms, IQR: 110.8 to 124.4; post: 134.8 ms, IQR: 126.9 to 141.3; P < 0.001). SlopeDRF correlated strongly with pDRF (r = 0.81), and T2-difference DRF also demonstrated strong correlation with pDRF (r = 0.80). Interreader agreement for DRF was excellent (ICC = 0.94).

CONCLUSION: Dynamic renal T2 mapping after intravenous furosemide administration shows strong correlation with Patlak-derived DRF from contrast-enhanced MRU and may provide a noninvasive, contrast- and radiation-free method for quantifying differential renal function in children.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Spogis J, Weitz M, Martirosian P, et al. Dynamic Renal T2-mapping After Furosemide Administration for Measurement of Differential Renal Function in Pediatric MR Urography. Invest Radiol. 2026. PMID: 41171010. doi:10.1097/RLI.0000000000001251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。